Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2013
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Xiaozhang Zheng, Kenneth W Bair, Paul Bauer, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Bioorganic & Medicinal Chemistry Letters|January 7, 2020
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)Peter S Dragovich, Pragya Adhikari, Robert A Blake, et al.
Elife|July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Elife|January 8, 2019
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Journal of Medicinal Chemistry|July 12, 2021
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast CancerJun Liang, Jason R Zbieg, Robert A Blake, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2013
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Xiaozhang Zheng, Kenneth W Bair, Paul Bauer, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Bioorganic & Medicinal Chemistry Letters|January 7, 2020
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)Peter S Dragovich, Pragya Adhikari, Robert A Blake, et al.
Elife|July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Elife|January 8, 2019
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancerJames D Joseph, Beatrice Darimont, Wei Zhou, et al.
Journal of Medicinal Chemistry|July 12, 2021
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast CancerJun Liang, Jason R Zbieg, Robert A Blake, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Pageof 10